Shopping Cart 0
Cart Subtotal
AED 0

Europe Blau Syndrome Market - Industry Trends and Forecast to 2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 15414

Details

Europe Blau syndrome market is projected to register a healthy CAGR of 12.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

Europe Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash and Inflammation), Route Of Administration (Oral, Parenteral, Topical and Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Tender and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland and Rest of Europe) Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of Europe Blau syndrome market are:

High adoption of biological therapies

Advancements in health care industry

Market Players:

The key market players for Europe Blau syndrome market are listed below:

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Swedish Orphan Biovitrum AB

Alkem Labs.

Accord Healthcare

F. Hoffmann-La Roche Ltd

Amneal Pharmaceuticals LLC

Centogene AG

Oncodesign

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE BLAU SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.10 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EUROPE BLAU SYNDROME MARKET: REGULATIONS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES

5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME

5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT

5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY

5.1.5 AVAILABILITY OF OFF LABEL DRUGS

5.2 RESTRAINTS

5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT

5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES

5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS

5.3 OPPORTUNITIES

5.3.1 RISING DISPOSABLE INCOME

5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES

5.3.3 EMERGING MARKETS

5.3.4 INCREASING RESEARCH AND DEVELOPMENT

5.4 CHALLENGES

5.4.1 LACK OF APPROVED DRUGS

5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS

5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS

6 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE BLAU SYNDROME MARKET

6.1 PRICE IMPACT

6.2 IMPACT ON DEMAND

6.3 IMPACT ON SUPPLY CHAIN

6.4 STRATEGIC DECISIONS FOR MANUFACTURERS

6.5 CONCLUSION

7 EUROPE BLAU SYNDROME MARKET, BY TYPE

7.1 OVERVIEW

7.2 TREATMENT

7.2.1 CORTICOSTEROIDS

7.2.1.1 PREDNISOLONE

7.2.1.2 COMBINATION CORTICOSTEROIDS

7.2.1.3 NAPROXEN

7.2.1.4 OTHERS

7.2.2 IMMUNOSUPPRESSANTS

7.2.2.1 METHOTREXATE

7.2.2.2 MYCOPHENOLATE MOFETIL

7.2.2.3 AZATHIOPRINE

7.2.2.4 OTHERS

7.2.3 TNF-? INHIBITORS

7.2.3.1 INFLIXIMAB

7.2.3.2 ADALIMUMAB

7.2.3.3 ETANERCEPT

7.2.3.4 OTHERS

7.2.4 OPTHALMIC MEDICATION

7.2.4.1 PREDNISOLONE ACETATE

7.2.4.2 TROPICAMIDE

7.2.4.3 OTHERS

7.2.5 INTERLEUKIN RECEPTOR

7.2.5.1 ANAKINRA

7.2.5.2 CANAKINUMAB

7.2.5.3 OTHERS

7.2.6 OTHERS

7.3 DIAGNOSIS

7.3.1 SCREENING

7.3.1.1 LAB TEST

7.3.1.1.1 BLOOD TEST

7.3.1.1.2 SALIVA TEST

7.3.1.1.3 OTHERS

7.3.1.2 IMAGING TEST

7.3.1.2.1 CT SCANS

7.3.1.2.2 ULTRASOUNDS

7.3.1.2.3 OTHERS

7.3.2 CONFIRMATORY TEST

7.3.2.1 SKIN BIOPSY

7.3.2.2 GENETIC TEST

7.3.2.3 OTHERS

8 EUROPE BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS

8.1 OVERVIEW

8.2 SKIN RASH

8.3 INFLAMMATION

8.3.1 GRANULOMATOUS DERMATITIS

8.3.2 SYNOVITIS

8.3.3 UVEITIS

8.3.4 GRANULOMATOUS ARTHRITIS

8.3.5 CHRONIC ARTHRITIS

8.3.6 OTHERS

9 EUROPE BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 ORAL

9.2.1 TABLET

9.2.2 CAPSULE

9.2.3 OTHERS

9.3 PARENTERAL

9.3.1 INTRAVENOUS

9.3.2 SUBCUTANEOUS

9.3.3 OTHERS

9.4 TOPICAL

9.4.1 OINTMENT

9.4.2 SOLUTION

9.4.3 OTHERS

9.5 OTHERS

10 EUROPE BLAU SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 DIAGNOSTICS CENTERS

10.4 CLINICS

10.5 HOME HEALTHCARE

10.6 OTHERS

11 EUROPE BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 HOSPITAL PHARMACY

11.3 RETAIL PHARMACY

11.4 ONLINE PHARMACY

11.5 DIRECT TENDER

11.6 OTHERS

12 EUROPE BLAU SYNDROME MARKET, BY GEOGRAPHY

12.1 EUROPE

12.1.1 GERMANY

12.1.2 FRANCE

12.1.3 U.K.

12.1.4 ITALY

12.1.5 NETHERLANDS

12.1.6 SPAIN

12.1.7 RUSSIA

12.1.8 SWITZERLAND

12.1.9 TURKEY

12.1.10 AUSTRIA

12.1.11 NORWAY

12.1.12 HUNGARY

12.1.13 LITHUANIA

12.1.14 IRELAND

12.1.15 POLAND

12.1.16 REST OF EUROPE

13 EUROPE BLAU SYNDROME MARKET, COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 SWOT

15 COMPANY PROFILES

15.1 NOVARTIS AG

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 AMGEN INC.

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENTS

15.3 PFIZER INC.

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENTS

15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 COMPANY SHARE ANALYIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENT

15.5 ABBVIE INC.

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENTS

15.6 ACCORD HEALTHCARE

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENTS

15.7 ALKEM LABS

15.7.1 COMPANY SNAPSHOT

15.7.2 REVENUE ANALYSIS

15.7.3 PRODUCT PORTFOLIO

15.7.4 RECENT DEVELOPMENT

15.8 AMNEAL PHARMACEUTICALS LLC

15.8.1 COMPANY SNAPSHOT

15.8.2 REVENUE ANALYSIS

15.8.3 PRODUCT PORTFOLIO

15.8.4 RECENT DEVELOPMENTS

15.9 CENTOGENE N.V.

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.10 F. HOFFMANN-LA ROCHE LTD

15.10.1 COMPANY SNAPSHOT

15.10.2 REVENUE ANALYSIS

15.10.3 PRODUCT PORTFOLIO

15.10.4 RECENT DEVELOPMENT

15.11 FULGENT GENETICS

15.11.1 COMPANY SNAPSHOT

15.11.2 REVENUE ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENT

15.12 HIKMA PHARMACEUTICALS PLC

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.13 INVITAE CORPORATION

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 MYLAN N.V.

15.14.1 COMPANY SNAPSHOT

15.14.2 REVENUE ANALYSIS

15.14.3 PRODUCT PORTFOLIO

15.14.4 RECENT DEVELOPMENTS

15.15 ONCODESIGN

15.15.1 COMPANY SNAPSHOT

15.15.2 REVENUE ANALYSIS

15.15.3 PRODUCT PORTFOLIO

15.15.4 RECENT DEVELOPMENT

15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

15.16.1 COMPANY SNAPSHOT

15.16.2 REVENUE ANALYSIS

15.16.3 PRODUCT PORTFOLIO

15.16.4 RECENT DEVELOPMENT

15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL)

15.17.1 COMPANY SNAPSHOT

15.17.2 REVENUE ANALYSIS

15.17.3 PRODUCT PORTFOLIO

15.17.4 RECENT DEVELOPMENTS

15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

15.18.1 COMPANY SNAPSHOT

15.18.2 REVENUE ANALYSIS

15.18.3 PRODUCT PORTFOLIO

15.18.4 RECENT DEVELOPMENTS

15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

16 QUESTIONNAIRE

17 RELATED REPORTS


List Of Figure

LIST OF FIGURES

FIGURE 1 EUROPE BLAU SYNDROME MARKET: SEGMENTATION

FIGURE 2 EUROPE BLAU SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE BLAU SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 EUROPE BLAU SYNDROME MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE BLAU SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE BLAU SYNDROME MARKET: SEGMENTATION

FIGURE 11 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE EUROPE BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 12 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BLAU SYNDROME MARKET IN 2020 & 2027

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF EUROPE BLAU SYNDROME MARKET

FIGURE 14 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019

FIGURE 15 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND)

FIGURE 16 EUROPE BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 17 EUROPE BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019

FIGURE 19 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)

FIGURE 20 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)

FIGURE 21 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE

FIGURE 22 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 23 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND)

FIGURE 24 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 25 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019

FIGURE 27 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND)

FIGURE 28 EUROPE BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027)

FIGURE 29 EUROPE BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 31 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)

FIGURE 32 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 33 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019)

FIGURE 35 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019)

FIGURE 36 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027)

FIGURE 37 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027)

FIGURE 38 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027)

FIGURE 39 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Swedish Orphan Biovitrum AB

Alkem Labs.

Accord Healthcare

F. Hoffmann-La Roche Ltd

Amneal Pharmaceuticals LLC

Centogene AG

Oncodesign

Company Profile

Company Profile Title

Europe Blau syndrome market is projected to register a healthy CAGR of 12.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

Europe Blau Syndrome Market, By Type (Treatment and Diagnosis), Therapeutic Areas (Skin Rash and Inflammation), Route Of Administration (Oral, Parenteral, Topical and Others), End User (Hospitals, Diagnostic Centers, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Direct Tender and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland and Rest of Europe) Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of Europe Blau syndrome market are:

High adoption of biological therapies

Advancements in health care industry

Market Players:

The key market players for Europe Blau syndrome market are listed below:

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Swedish Orphan Biovitrum AB

Alkem Labs.

Accord Healthcare

F. Hoffmann-La Roche Ltd

Amneal Pharmaceuticals LLC

Centogene AG

Oncodesign

READ MORE

Scope

TABLE OF CONTENTS

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE BLAU SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 THERAPEUTIC AREAS OF BLAU SYNDROME LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.10 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EUROPE BLAU SYNDROME MARKET: REGULATIONS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 HIGH ADOPTION OF BIOLOGICAL THERAPIES

5.1.2 EMERGENCE OF DRUGS USED TO TREAT SYMPTOMS ASSOCIATED WITH BLAU SYNDROME

5.1.3 HIGH DEMAND OF DISEASE SPECIFIC TREATMENT

5.1.4 ADVANCEMENTS IN HEALTH CARE INDUSTRY

5.1.5 AVAILABILITY OF OFF LABEL DRUGS

5.2 RESTRAINTS

5.2.1 UNAVAILABILITY AND UNAFFORDABILITY OF EFFECTIVE TREATMENT

5.2.2 POOR DIAGNOSIS RATE IN SOME DEVELOPING COUNTRIES

5.2.3 LARGE NUMBER OF SIDE EFFECTS OF AVAILABLE DRUGS

5.3 OPPORTUNITIES

5.3.1 RISING DISPOSABLE INCOME

5.3.2 RISING STRATEGIC INITIATIVES BY PHARMACEUTICAL COMPANIES

5.3.3 EMERGING MARKETS

5.3.4 INCREASING RESEARCH AND DEVELOPMENT

5.4 CHALLENGES

5.4.1 LACK OF APPROVED DRUGS

5.4.2 HIGH COST ASSOCIATED WITH SYNDROME DIAGONSIS

5.4.3 LACK OF SKILLED RESOURCE FOR PERFORMING GENETIC TESTS

6 IMPACT OF COVID-19 PANDEMIC ON THE EUROPE BLAU SYNDROME MARKET

6.1 PRICE IMPACT

6.2 IMPACT ON DEMAND

6.3 IMPACT ON SUPPLY CHAIN

6.4 STRATEGIC DECISIONS FOR MANUFACTURERS

6.5 CONCLUSION

7 EUROPE BLAU SYNDROME MARKET, BY TYPE

7.1 OVERVIEW

7.2 TREATMENT

7.2.1 CORTICOSTEROIDS

7.2.1.1 PREDNISOLONE

7.2.1.2 COMBINATION CORTICOSTEROIDS

7.2.1.3 NAPROXEN

7.2.1.4 OTHERS

7.2.2 IMMUNOSUPPRESSANTS

7.2.2.1 METHOTREXATE

7.2.2.2 MYCOPHENOLATE MOFETIL

7.2.2.3 AZATHIOPRINE

7.2.2.4 OTHERS

7.2.3 TNF-? INHIBITORS

7.2.3.1 INFLIXIMAB

7.2.3.2 ADALIMUMAB

7.2.3.3 ETANERCEPT

7.2.3.4 OTHERS

7.2.4 OPTHALMIC MEDICATION

7.2.4.1 PREDNISOLONE ACETATE

7.2.4.2 TROPICAMIDE

7.2.4.3 OTHERS

7.2.5 INTERLEUKIN RECEPTOR

7.2.5.1 ANAKINRA

7.2.5.2 CANAKINUMAB

7.2.5.3 OTHERS

7.2.6 OTHERS

7.3 DIAGNOSIS

7.3.1 SCREENING

7.3.1.1 LAB TEST

7.3.1.1.1 BLOOD TEST

7.3.1.1.2 SALIVA TEST

7.3.1.1.3 OTHERS

7.3.1.2 IMAGING TEST

7.3.1.2.1 CT SCANS

7.3.1.2.2 ULTRASOUNDS

7.3.1.2.3 OTHERS

7.3.2 CONFIRMATORY TEST

7.3.2.1 SKIN BIOPSY

7.3.2.2 GENETIC TEST

7.3.2.3 OTHERS

8 EUROPE BLAU SYNDROME MARKET, BY THERAPEUTIC AREAS

8.1 OVERVIEW

8.2 SKIN RASH

8.3 INFLAMMATION

8.3.1 GRANULOMATOUS DERMATITIS

8.3.2 SYNOVITIS

8.3.3 UVEITIS

8.3.4 GRANULOMATOUS ARTHRITIS

8.3.5 CHRONIC ARTHRITIS

8.3.6 OTHERS

9 EUROPE BLAU SYNDROME MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 ORAL

9.2.1 TABLET

9.2.2 CAPSULE

9.2.3 OTHERS

9.3 PARENTERAL

9.3.1 INTRAVENOUS

9.3.2 SUBCUTANEOUS

9.3.3 OTHERS

9.4 TOPICAL

9.4.1 OINTMENT

9.4.2 SOLUTION

9.4.3 OTHERS

9.5 OTHERS

10 EUROPE BLAU SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 DIAGNOSTICS CENTERS

10.4 CLINICS

10.5 HOME HEALTHCARE

10.6 OTHERS

11 EUROPE BLAU SYNDROME MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 HOSPITAL PHARMACY

11.3 RETAIL PHARMACY

11.4 ONLINE PHARMACY

11.5 DIRECT TENDER

11.6 OTHERS

12 EUROPE BLAU SYNDROME MARKET, BY GEOGRAPHY

12.1 EUROPE

12.1.1 GERMANY

12.1.2 FRANCE

12.1.3 U.K.

12.1.4 ITALY

12.1.5 NETHERLANDS

12.1.6 SPAIN

12.1.7 RUSSIA

12.1.8 SWITZERLAND

12.1.9 TURKEY

12.1.10 AUSTRIA

12.1.11 NORWAY

12.1.12 HUNGARY

12.1.13 LITHUANIA

12.1.14 IRELAND

12.1.15 POLAND

12.1.16 REST OF EUROPE

13 EUROPE BLAU SYNDROME MARKET, COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 SWOT

15 COMPANY PROFILES

15.1 NOVARTIS AG

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 AMGEN INC.

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENTS

15.3 PFIZER INC.

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENTS

15.4 JANSSEN PHARMACEUTICALS, INC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 COMPANY SHARE ANALYIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENT

15.5 ABBVIE INC.

15.5.1 COMPANY SNAPSHOT

15.5.2 REVENUE ANALYSIS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENTS

15.6 ACCORD HEALTHCARE

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENTS

15.7 ALKEM LABS

15.7.1 COMPANY SNAPSHOT

15.7.2 REVENUE ANALYSIS

15.7.3 PRODUCT PORTFOLIO

15.7.4 RECENT DEVELOPMENT

15.8 AMNEAL PHARMACEUTICALS LLC

15.8.1 COMPANY SNAPSHOT

15.8.2 REVENUE ANALYSIS

15.8.3 PRODUCT PORTFOLIO

15.8.4 RECENT DEVELOPMENTS

15.9 CENTOGENE N.V.

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.10 F. HOFFMANN-LA ROCHE LTD

15.10.1 COMPANY SNAPSHOT

15.10.2 REVENUE ANALYSIS

15.10.3 PRODUCT PORTFOLIO

15.10.4 RECENT DEVELOPMENT

15.11 FULGENT GENETICS

15.11.1 COMPANY SNAPSHOT

15.11.2 REVENUE ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENT

15.12 HIKMA PHARMACEUTICALS PLC

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENTS

15.13 INVITAE CORPORATION

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 MYLAN N.V.

15.14.1 COMPANY SNAPSHOT

15.14.2 REVENUE ANALYSIS

15.14.3 PRODUCT PORTFOLIO

15.14.4 RECENT DEVELOPMENTS

15.15 ONCODESIGN

15.15.1 COMPANY SNAPSHOT

15.15.2 REVENUE ANALYSIS

15.15.3 PRODUCT PORTFOLIO

15.15.4 RECENT DEVELOPMENT

15.16 SALIX PHARMACEUTICALS (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

15.16.1 COMPANY SNAPSHOT

15.16.2 REVENUE ANALYSIS

15.16.3 PRODUCT PORTFOLIO

15.16.4 RECENT DEVELOPMENT

15.17 SWEDISH ORPHAN BIOVITRUM AB (PUBL)

15.17.1 COMPANY SNAPSHOT

15.17.2 REVENUE ANALYSIS

15.17.3 PRODUCT PORTFOLIO

15.17.4 RECENT DEVELOPMENTS

15.18 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

15.18.1 COMPANY SNAPSHOT

15.18.2 REVENUE ANALYSIS

15.18.3 PRODUCT PORTFOLIO

15.18.4 RECENT DEVELOPMENTS

15.19 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

16 QUESTIONNAIRE

17 RELATED REPORTS


List Of Figure

LIST OF FIGURES

FIGURE 1 EUROPE BLAU SYNDROME MARKET: SEGMENTATION

FIGURE 2 EUROPE BLAU SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE BLAU SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 EUROPE BLAU SYNDROME MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE BLAU SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE BLAU SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE BLAU SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE BLAU SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE BLAU SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE BLAU SYNDROME MARKET: SEGMENTATION

FIGURE 11 HIGH ADOPTION OF BIOLOGICAL THERAPIES AND HIGH DEMAND OF DISEASE SPECIFIC TREATMENT IS DRIVING THE EUROPE BLAU SYNDROME MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 12 TREATMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BLAU SYNDROME MARKET IN 2020 & 2027

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF EUROPE BLAU SYNDROME MARKET

FIGURE 14 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019

FIGURE 15 EUROPE BLAU SYNDROME MARKET: BY TYPE, 2019-2027 (USD THOUSAND)

FIGURE 16 EUROPE BLAU SYNDROME MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 17 EUROPE BLAU SYNDROME MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019

FIGURE 19 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, 2019-2027 (USD THOUSAND)

FIGURE 20 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)

FIGURE 21 EUROPE BLAU SYNDROME MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE

FIGURE 22 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 23 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND)

FIGURE 24 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 25 EUROPE TREATMENT IN BLAU SYNDROME MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019

FIGURE 27 EUROPE BLAU SYNDROME MARKET: BY END USER, 2019-2027 (USD THOUSAND)

FIGURE 28 EUROPE BLAU SYNDROME MARKET: BY END USER, CAGR (2020-2027)

FIGURE 29 EUROPE BLAU SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 31 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)

FIGURE 32 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 33 EUROPE BLAU SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 EUROPE BLAU SYNDROME MARKET: SNAPSHOT (2019)

FIGURE 35 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019)

FIGURE 36 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2020 & 2027)

FIGURE 37 EUROPE BLAU SYNDROME MARKET: BY COUNTRY (2019 & 2027)

FIGURE 38 EUROPE BLAU SYNDROME MARKET: BY TYPE (2020-2027)

FIGURE 39 EUROPE BLAU SYNDROME MARKET: COMPANY SHARE 2019 (%)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Novartis AG

Pfizer Inc.

AbbVie Inc.

Amgen Inc.

Janssen Pharmaceuticals, Inc.(A Subsidiary of Johnson & Johnson Services Inc.)

Mylan N.V.

Hikma Pharmaceuticals PLC

Swedish Orphan Biovitrum AB

Alkem Labs.

Accord Healthcare

F. Hoffmann-La Roche Ltd

Amneal Pharmaceuticals LLC

Centogene AG

Oncodesign